Glioma Classification and MD Note Generation Guide

Gliomas are heterogeneous. They change and adapt in response to the composition of their microenvironment and response to therapy. Therefore, developing molecular classifiers that provide meaningful ways to stratify patients remains a significant challenge for the field.

The latest WHO CNS5 2021 (Louis 2021) suggests a seven-layer integrated diagnosis comprising eight genomic and five protein signatures. The seven molecular layers for an integrated gliomas diagnosis are:

  1.  Isocitrate dehydrogenase (IDH1) mutations.

  2.  α-thalassemia/mental-retardation-syndrome-X-linked gene (ATRX) expression.

  3.  1p/19q co-deletion.

  4.  CDKN2A/B homozygous deletion on 9p21.

  5.  TERT promoter mutation/EGFR gene amplification and/or chromosomes 7 gain and 10 loss (+7/–10).

  6.  Histone H3 G34R/V mutations.

  7.  Histone H3 K27M/ mutations.

For the first time, molecular features have been explicitly added to the grading schema. For example, an IDH-wildtype astrocytoma with low-grade histologic features can be considered grade 4 (glioblastoma) in the presence of nuclear ATRX, EGFR amplification, TERT promoter mutation, or the combined gain of chromosome 7 and loss of chromosome 10 [+7/-10]. 


Pathology and Prognosticators

years.

Enter as percentage.

Glioma Markers








PubMed Search